Introduction {#s1}
============

Glioblastoma (GBM) is the most common malignant tumor of the brain. GBM rapidly proliferates and invades the central nervous system. Due to his invasive characteristics, the prognosis of GBM patients is very poor, despite of the treatment that currently consists of surgical resection followed by radiotherapy plus concomitant and adjuvant temozolomide [@pone.0057145-Stupp1]. Targeted therapies have been introduced, based on information obtained from molecular studies of the tumor tissue (usually shown at MRI as an enhanced lesion, ET) [@pone.0057145-Bai1]. However, no clear survival benefit has been demonstrated, probably because tumor tissue represents the last step of tumorigenesis, involving some alterations allowing tumor-cells to survive. Since recurrence in peritumoral tissue occurs in about 95% of patients [@pone.0057145-Mangiola1], getting a deeper insight into the biology of the brain adjacent to-tumor (BAT) is of great interest. It has been demonstrated that the expression of a series of elements and amino-acids is altered in the BAT [@pone.0057145-Bakshi1], [@pone.0057145-DeMicheli1], [@pone.0057145-Dehnhardt1], [@pone.0057145-Stevenson1], [@pone.0057145-Nowacki1]. It has been shown that even in the absence of tumor cells, kinases involved in cell proliferation, migration and apoptosis are expressed in BAT together with molecules linked to stemness, invasion and neo-angiogenesis, which might indicate that BAT is undergoing transformation [@pone.0057145-Lama1], [@pone.0057145-Mangiola2], [@pone.0057145-Sica1]. To support this hypothesis, we carried out a gene expression profile and a genomic analysis of BAT to detect alterations that may indicate the appearance of neoplastic features. To achieve our aim, we have compared the gene expression profile of tissue samples from ET, BAT, and normal white matter (CTRL) and have analyzed the BAT with an Array-CGH to detect genomic alterations.

Methods {#s2}
=======

Patients and Specimens {#s2a}
----------------------

From January 2006 to December 2007, 60 adults were operated for primary GBM at our Institute. We selected 11 patients with tumor location far from eloquent areas. Among them, 5 patients did not present tumor cells in BAT and were included in the study. Tumor was removed with wide tumor-free resection margins of 1--2 cm. One part of the ET (without areas of necrosis) was immediately fixed in 10% neutral buffered formalin for histological analysis and the second one was immediately frozen on dry ice for molecular analysis. BAT specimens were obtained using a sampling-grid ([Figure1](#pone-0057145-g001){ref-type="fig"}A). CTRL specimens were derived from 4 patients at the same ages operated for deep cavernomas with radiological signs of recent bleeding. These samples were used as controls in molecular analyses.

![Tissue sampling.\
(A) Tissue specimen opened in a book-wise fashion before sampling; white asterisk: tumor; black asterisk: BAT. Sampling-grid: each tissue specimen was generally divided into eight parts, and BAT samples for molecular analyses were contiguous to those used for histology; in this way, a higher probability of homogeneity between samples used for histology and gene expression analysis, quantitative real-time PCR, western blot analysis and array-CGH was obtained. (B) H&E staining of BAT with absence of morphologically neoplastic cells. (C) GFAP staining, showing reactive astrocytes, with stellar morphology. (D) Ki67/MIB-1 was always \<1%. (E) Gene-microarray analysis.](pone.0057145.g001){#pone-0057145-g001}

Ethics statement. All patients provided written consent to use their specimens for research purposes, none of them was identifiable. The study was approved by the local ethics committee (Catholic University Ethics Committee, Rome). The ethical principles of the declaration of Helsinki were strictly followed.

Histopathology {#s2b}
--------------

All histological samples were reviewed by a board-certified neuropathologist (LL) and all tumours were classified as glioblastoma (WHO IV). Multiple levels of each paraffin block of samples used for research purposes (ET, BAT and CTRL) were thoroughly examined. No tumor cells were seen in BAT samples used in this study.

Gene Expression Analysis {#s2c}
------------------------

For global gene expression analysis we used 4 CTRL samples, 5 ET samples (ET1, ET2, ET3, ET4, ET5), and 7 BAT samples (BAT1, BAT3, BAT5; in two patient samples were taken from two different peritumoral areas: BAT2, BAT2R; BAT4, BAT4R). Total RNA was extracted using Trizol Reagent followed by clean-up and DNase digestion on an RNeasy spin column. RNA was quantified by UV spectrophotometer and quality was assessed on agarose gel. RNA was processed for use on the Affymetrix Human Expression HG-U133A arrays (Affymetrix, Santa Clara, CA) according to manufacturer's instructions. Briefly, 2.5 µg of each RNA was converted into double-strand cDNA using a T7-(dT)24 primer. cDNA was used as template to generate biotinylated cRNA during an in vitro transcription step. Labeled cRNA was purified, chemically fragmented and 15 µg were hybridized on the array for 16 h at 45°C in a rotisserie oven set at 60 rpm. The arrays were then stained in the Affymetrix Fluidic Station and scanned twice using the Agilent Gene Array scanner 2500.

The expression data were generated by Affymetrix microarray suite 5.0 software and loaded into GeneSpring Expression Analysis version 7.3 software. Raw intensities from each chip were normalized using the GC-RMA method completed by an additional normalization to the median for each gene. Data were filtered to eliminate genes displaying an averaged intensity inferior to the global array background.

Datasets were then assigned to the three experimental groups: CTRL, ET, and BAT, and the averaged log2 intensities of biological replicates were used for further analysis. Homogeneity of sample groups was verified by analysis of the principal component (PCA). Pre-filtered data were submitted to statistical analysis (t-test; P\<0.05 with FDR correction) to identify genes differentially expressed between ET and BAT samples, and between BAT and CTRL. Genes with a fold change of gene expression \>2 between CTRL and BAT samples were subjected to hierarchical clustering using Pearson correlation coefficient. Results have been deposited in NCBI Gene Expression Omnibus <http://www.ncbi.nlm.nih.gov/projects/geo/> (accession number: GSE13276).

Quantitative Real-time PCR {#s2d}
--------------------------

About 1.5 µg of total RNA were reverse-transcribed by SuperScript III, using random hexamer primers (Invitrogen, Carlsbad, CA, USA). Quantitative real-time PCR (qPCR) was carried out with LightCycler technology (Roche Molecular Biochemicals, Indianapolis, IN, USA). Oligonucleotide primers ([Table 1](#pone-0057145-t001){ref-type="table"}) were designed using Primer3 software (<http://frodo.wi.mit.edu/>). Cycling conditions: 95°C for 10 minutes, 40 cycles of 95°C for 10 seconds, 58°C for 7 seconds, 72°C for 8 seconds, followed by a melt curve analysis immediately begun to rule out synthesis of unspecific products. Crossing points (Cp) of real-time-PCR curves were determined by the Light cycler software using the second derivative maximum method. For each target, two independent amplifications were performed and the mean value was used for further analysis. The 2−ΔΔCt method was applied to calculate fold changes in the expression levels of the genes. Statistical analysis was performed using t-test.

10.1371/journal.pone.0057145.t001

###### Primer sequences.

![](pone.0057145.t001){#pone-0057145-t001-1}

  Gene                                 Primer forward (5′--3′)                     Primer reverse (5′--3′)
  ----------------- ------------------------------------------------------------- -------------------------
  *TAZ*                                 CAGCAATGTGGATGAGATGG                        TCATTGAAGAGGGGGATCAG
  *KLRC1*                               CATCCTCATGGATTGGTGTG                        GATCCACACTGGGCTGATTT
  *EGFR*                                TGCTGGATGATAGACGCAGA                        GGCACGGTAGAAGTTGGAGT
  *IGFBP5*                              CAGGGGTCTGGTCTCTTTGA                        GTGGAGTGAGGCACGAATCT
  *SRP1*                                TGAGGACGAGGTGGATGTTA                        CCCCTGTAGCCATACTTTGC
  *USH1C*                               GAAGAAGACTGGGGCTCAAA                        AAATCCTGCTCTCCCTGCTC
  *ID3*                                 GGAGCTTTTGCCACTGACTC                        CAGGAAGGGATTTGGTGAAG
  *18S ribosomal*    Qiagen Hs_RRN18S_1\_SG QuantiTect_Primer_Assay (QT00199367)  

Western-blot Analysis {#s2e}
---------------------

The presence of KLRC1 (killer cell lectin-like receptor sub family C, member1) in 3 independent specimens of BAT and 3 CTRL samples was evaluated by western-blot analysis. Forty µg of proteins were resolved by 12% SDS-PAGE and transferred to PVDF membrane. Non specific binding was blocked with 5% nonfat dry milk for 1 h. The blots were probed with a 1∶500 dilution of mouse anti-human KLRC1 antibody (Abnova Corporation.) or a 1∶10.000 dilution of mouse anti-human β-actin, overnight at 4°C. Biotinylated anti-mouse IgG (dilution 1∶1000; Vector Laboratories, Burlingame, CA, USA) was used as secondary antibody for 1 h at RT. After washes in PBS containing 0.1% Tween-20, membranes were incubated for 30 min at RT with Vectastain Elite ABC reagent (Vector Laboratories), and antibody reactivity was visualized by incubation with diaminobenzidine.

Array-CGH {#s2f}
---------

DNA from 3 frozen ET samples (ET1, ET2 and ET3) and 3 matched BAT samples (BAT1, BAT2R and BAT3) was extracted using QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). The rest of frozen tissue of BAT1, BAT2R and BAT3 samples was then evaluated in frozen sections and no tumor cells were identified.

Oligonucleotide aCGH was performed using the Agilent Human Genome CGH microarray 4×44K, (Agilent Technologies Santa Clara, CA, USA), with an average resolution of 75 kb, following the manufacturer's instructions. Each sample was paired with a sex-matched commercial control DNA (Promega, Madison, WI, USA), and hybridized twice in a dye-swap experiment, in order to minimize false positive calls. The arrays were analyzed using GenePix 4000B scanner (Axon, Union City, CA, USA) and Feature Extraction V.9.5.1 software. A graphical overview of the results was obtained using CGH Analytics V.3.5.14 software. Combined dye-swapped experiments were analyzed with ADM-2 algorithm at 3 different thresholds: 4, 5 and 6, with Centralization and Fuzzy Zero corrections turned on, with the purpose of detecting low grade mosaicisms. The percentage of abnormal cells was inferred using the formula proposed by Valli et al. [@pone.0057145-Valli1].

Immunohistology {#s2g}
---------------

Both immunohistochemical and immunofluorescence analyses were performed in paraffin-embedded tissue sections (5 µm thick) from ET and BAT. All samples were deparaffinized and rehydrated. Immunohistochemical and immunofluorescence analyses were performed considering the results of the gene expression analyses. In particular, the expression of some proteins whose genes were over-expressed in the BAT compared with CTRL was analyzed. Moreover, immunofluorescence analysis for CD133 protein was performed.

For immunohistochemistry, after the endogen peroxidase blocking, sections were incubated with monoclonal anti-human GFAP (1∶100; clone 273807; R&D SYSTEMS, Minneapolis, MN, USA), anti-human Ki-67 (1∶100; clone MIB-1; Dako, Glostrup, Denmark) antibodies or with a polyclonal anti-human TAZ antibody (1∶60; LifeSpan Biosciences, Seattle, WA, USA) overnight at 4°C. Subsequently, slides were incubated with a HRP/Fab polymer conjugate (SuperPicTure Polymer Detection Kit, Invitrogen, Camarillo, CA, USA). The immunostaining for Epidermal Growth Factor Receptor (EGFR) and CD99 was performed using the monoclonal antibodies anti- human EGFR (1∶100; Clone E30; Dako) and CD99 (1∶100; clone 12E7; Dako) on an autostainer (Dako Autostainer Plus Link, Dako). The antigen retrieval was performed using pronase digestion (ProTaqs® Pronase Digest, Germany) and En Vision™ Flex Target Retrieval Solution High pH (Dako) for EGFR and CD99, respectively.

Immunopositive cells were visualized by brown DAB (Vector Laboratories, Inc., Burlingame, CA, USA) staining. The nuclei were lightly counterstained with Mayer's hematoxylin.

Tonsil sections were used as positive controls for EGFR and CD99 expression.

For CD133 immunofluorescence analysis on ET and BAT, the sections were incubated for 12 h at 4°C with the polyclonal anti-human CD133 (1∶50; Spring Bioscience, CA, USA) and were then treated with the secondary antibody (goat anti-rabbit Alexa Fluor 488; 1∶200; Invitrogen) for 1 h at room temperature (RT).

For double-labeling immunofluorescence analysis, histological sections were incubated for 20 h at 4°C with the anti-GFAP and TAZ antibodies as described above. The next day, the slides were incubated with a mixture of the following secondary antibodies: goat anti-rabbit Alexa Fluor 488 (1∶250; Invitrogen) and red fluorescent cyanine donkey anti-mouse Cy3 (1∶200; Jackson Immunoresearch Laboratories) for 2 h at RT. The sections were coverslipped with Vectashield Mounting Medium with DAPI (Vector Laboratories) and examined with a confocal laser scanning system (TCS-SP2, Leica Microsystems, GmbH, Wetzlar, Germany) equipped with an Ar/ArKr laser and a HeNe laser for 488 nm and 543 nm excitation, respectively. For each analyzed field, Z-stack series of 4--5 µm-thick were acquired as images (1024×1024 pixels), recorded at intervals of 0.20 µm, and then projection images were created and processed using the Leica software. MDA-MB-231, a breast cancer cell line expressing moderate TAZ levels, was used as positive control for TAZ expression [@pone.0057145-Chan1]. In each experiment, negative controls without the primary antibody were included to check for nonspecific staining.

Results {#s3}
=======

Histopathology {#s3a}
--------------

The CTRL samples displayed a variable degree of gliosis due to bleeding of the cavernomas and subsequent edema, as it was indicated by the presence of GFAP-reactive astrocytes, with a characteristic dendritic morphology and abundant eosinophilic cytoplasm and with large eccentric nuclei (data not shown). The number of Ki67/MIB1 positive cells was lower than 1% (data not shown).

In the ET samples, the number of Ki67/MIB1 positive cells varied between 10% and 60% (data not shown).

Microarray Analysis {#s3b}
-------------------

Genome-wide expression profiles of 5 ET samples, 7 BAT samples from 5 patients, and 4 CTRL white matter biopsies were analysed. The representation of the samples in a three-dimensional (3D) space clearly distinguished 3 groups corresponding to the 3 tissues ([Figure 2](#pone-0057145-g002){ref-type="fig"}). The CTRL and BAT samples were pooled in 2 distinct groups.

![PCA 3D view for gene expression profiles of samples of the three experimental conditions (red: CTRL; yellow: ET; blue: BAT).\
Every dot represents a sample. PCA was based on log^2^ ratios and the expression profiles were performed across the 14,500 genes of the human HG-U133A array. The first 3 principal components are plotted. PCA representation shows samples segregation according to their tissue origin.](pone.0057145.g002){#pone-0057145-g002}

Differential Gene Expression between ET and BAT {#s3c}
-----------------------------------------------

Molecular analysis of ET and BAT samples showed significant changes in the expression of 1,323 genes. Genes with at least 10-fold difference in the expression level were further analyzed ([Table 2](#pone-0057145-t002){ref-type="table"}). Twenty genes were over-expressed in ET when compared to BAT, while 45 genes were down-regulated. The expression of the angiogenesis-related genes *VEGF* and *ANGPT2* was increased in ET. Genes associated with cell growth (*IGFBP2*, *GAP43*), along with the cell cycle activator *CKS2*, were over-expressed. Most of the highly up-regulated genes encoded proteins associated with the extracellular matrix formation, including *COL4A1, COL4A2, COL1A1, COL3A1, COL1A2*. The 45 genes showing significantly decreased expression in ET were more heterogeneous with respect to the functions of their gene products. The majority of these genes were involved in the development of the nervous system (*MOG, RAPGEF5, GRM3, SH3GL3, NINJ2, UGT8, MOBP, MBP*).

10.1371/journal.pone.0057145.t002

###### Selection of the genes significantly different between ET and BAT with a 10*-*fold difference in expression levels.

![](pone.0057145.t002){#pone-0057145-t002-2}

  Genebank                                                                        Description                                   Symbol     FC     Corrected p-value
  ------------------------------------------------ -------------------------------------------------------------------------- ---------- ------- -------------------
  **Genes down-regulated in ET compared to BAT**                                                                                                 
  ***Central nervous system development***                                                                                                       
  NM_006501                                                     myelin-associated oligodendrocyte basic protein                  MOBP     −34.4         0.006
  NM_003027                                                                  SH3-domain GRB2-like 3                             SH3GL3    −31.7         0.022
  NM_002385                                                                   myelin basic protein                               MBP      −29.2         0.029
  NM_002433                                                           myelin oligodendrocyte glycoprotein                        MOG      −24.2         0.018
  NM_016533                                                                        ninjurin 2                                   NINJ2      −16          0.039
  NM_000840                                                            glutamate receptor, metabotropic 3                        GRM3     −13.8         0.035
  NM_003360                                                                UDP glycosyltransferase 8                             UGT8     −12.9         0.004
  NM_012294                                                         Rap guanine nucleotide exchange factor 5                   RAPGEF5     −12          0.03
  ***Signal transduction***                                                                                                                      
  NM_002371                                                           mal, T-cell differentiation protein                        MAL      −30.6         0.017
  AL524520                                                               G protein-coupled receptor 49                          GPR49     −12.7         0.045
  T16257                                                                 G protein-coupled receptor 37                          GPR37     −12.6  
  NM_005709                                                                    Usher syndrome 1C                                USH1C      −10          0.014
  ***Cell adhesion/motility***                                                                                                                   
  L35594                                                                           autotaxin                                     ATX      −22.3         0.037
  X98405                                                                 myelin associated glycoprotein                          MAG      −18.7         0.018
  U88870                                                                         peanut-like 2                                  PNUTL2    −14.7         0.042
  NM_016950                                         sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3    SPOCK3     −11          0.006
  NM_003628                                                                      plakophilin 4                                   PKP4     −10.8         0.017
  ***Transport***                                                                                                                                
  NM_001063                                                                       transferrin                                     TF       −15          0.004
  NM_018478                                                                        dysbindin                                    DBNDD2    −12.4         0.026
  NM_012128                                                   chloride channel, calcium activated, family member 4              CLCA4     −11.8         0.004
  NM_007168                                                       ATP-binding cassette, sub-family A member 8                   ABCA8     −11.3         0.007
  BC000585                                                solute carrier organic anion transporter family, member 3A1          SLCO3A1     −10          0.022
  ***Protein metabolism***                                                                                                                       
  NM_002774                                                                       kallikrein 6                                   KLK6      −32          0.004
  NM_002570                                                        paired basic amino acid cleaving system 4                    PACE4     −28.5         0.043
  NM_000049                                                                      aspartoacylase                                  ASPA     −24.2         0.032
  NM_004476                                                                    folate hydrolase 1                               FOLH1     −18.5         0.031
  NM_004616                                                           transmembrane 4 superfamily member 3                      TM4SF3    −10.8         0.005
  ***Transcription regulation***                                                                                                                 
  NM_014682                                                             suppression of tumorigenicity 18                         ST18      −30          0.028
  NM_014717                                                                 zinc finger protein 536                             ZNF536    −16.3         0.03
  NM_013279                                                            chromosome 11 open reading frame 9                      C11orf9    −10.7         0.017
  ***Cytoskeleton organization***                                                                                                                
  AU157109                                                                      KIAA1598 protein                               KIAA1598   −14.8         0.048
  AW242297                                                              microtubule-associated protein 7                         MAP7     −13.2         0.037
  ***Other processes***                                                                                                                          
  AA191573                                                                       synaptojanin 2                                 SYNJ2     −35.4         0.022
  AB032981                                                     PAIP2B HGNC binding protein interacting protein 2B               PAIP2B     −27          0.047
  AB007880                                                                   KIAA0420 gene product                             KIAA0420   −22.5         0.039
  AI803302                                                                    LIM domain binding 3                               LDB3     −20.4         0.028
  U56725                                                                 Human heat shock protein mRNA,                         HSPA2      −20          0.038
  BC003169                                                                      calpain 3, (p94)                                CAPN3     −18.2         0.027
  NM_000954                                                         prostaglandin D2 synthase 21 kDa (brain)                    PTGDS     −17.6         0.026
  NM_024306                                                                 fatty acid 2-hydroxylase                             FA2H     −13.5         0.038
  NM_022126                                            phospholysine phosphohistidine inorganic pyrophosphate phosphatase        LHPP      −13          0.041
  AF318616                                                                       synaptojanin 2                                 SYNJ2      −12          0.027
  NM_014210                                                           ecotropic viral integration site 2A                       EVI2A     −11.7         0.039
  NM_024897                                                      progestin and adipoQ receptor family member VI                 PAQR6      −11          0.002
  NM_003657                                                          breast carcinoma amplified sequence 1                      BCAS1     −10.6         0.015
  Genes over-expressed in ET compared to BAT                                                                                                     
  ***Immune system***                                                                                                                            
  NM_002852                                                   pentaxin-related gene, rapidly induced by IL-1 beta                PTX3     18.2          0.028
  NM_012072                                                    complement component 1,q subcomponent, receptor 1                C1QR1     16.2          0.039
  ***Extracellular matrix formation***                                                                                                           
  NM_000089                                                                collagen, type I, alpha 2                            COL1A2    26.8          0.014
  X05610                                                                   collagen, type IV, alpha 2                           COL4A2    13.9          0.017
  K01228                                                                   collagen, type I, alpha 1                            COL1A1    13.0          0.018
  NM_001845                                                                collagen, type IV, alpha 1                           COL4A1    11.8          0.014
  NM_000900                                                                    matrix Gla protein                                MGP      10.4          0.002
  X02761                                                                         fibronectin 1                                   FN1      10.2          0.03
  AF130082                                                                collagen, type III, alpha 1                           COL3A1    10.0          0.008
  ***Angiogenesis***                                                                                                                             
  AF022375                                                             vascular endothelial growth factor                        VEGF     16.0          0.032
  NM_001147                                                                      angiopoietin 2                                 ANGPT2    10.4          0.004
  ***Cell cycle***                                                                                                                               
  NM_001827                                                        CDC28 protein kinase regulatory subunit 2                     CKS2     12.6          0.017
  ***Cell growth & proliferation***                                                                                                              
  NM_000597                                                   insulin-like growth factor binding protein 2, 36 kDa              IGFBP2    35.8          0.017
  NM_003254                                                         tissue inhibitor of metalloproteinase 1                     TIMP1     16.6          0.037
  NM_002045                                                               growth associated protein 43                          GAP43     12.9          0.039
  ***Other processes***                                                                                                                          
  NM_000358                                                     transforming growth factor, beta-induced, 68 kDa                TGFBI     26.6          0.026
  BC001886                                                          ribonucleotide reductase M2 polypeptide                      RRM2     21.1          0.022
  NM_014736                                                                  KIAA0101 gene product                             KIAA0101   13.3          0.046
  BG435404                                                               ADP-ribosylation factor-like 7                          ARL7     10.7          0.006
  AI082078                                                                      actinin, alpha 1                                ACTN1     10.2          0.015

Differential Gene Expression between BAT and CTRL {#s3d}
-------------------------------------------------

Statistical analysis associated with a threshold approach (cut-off: 2) resulted in 57 genes showing significantly different expression in BAT and CTRL. This dataset was submitted to hierarchical clustering to determine the gene expression pattern in all tissue types, including also ET specimens ([Figure 3](#pone-0057145-g003){ref-type="fig"}).

![Hierarchical cluster analysis.\
Hierarchical cluster analysis based on expression of 63 transcripts (57 genes) that differed between BAT and CTRL samples (P\<0.05) and had greater than 2-fold change between the means of the two tissue types. Each row represents a specific transcript; each column represents a tissue sample harvested from independent patients (R:technical replicate).](pone.0057145.g003){#pone-0057145-g003}

Molecular profiling showed 15 genes over-expressed and 42 genes down-regulated in BAT ([Table 3](#pone-0057145-t003){ref-type="table"}). Genes belonging to 2 main relevant biological processes were particularly deregulated in BAT. In fact, genes associated with growth and proliferation (*CSRP2, TAZ, ID3, DTNA*) and cell motility/adhesion (*HIST2H2AA, EGFR, IGFBP5, VCAM1, CD99*) were up-regulated while genes involved in neurogenesis (*SYNJ1, NBEA, SERPINI1, CNTNAP2, RELN*) were largely down-regulated in BAT. Several tumour suppressor genes (*BAI3, PEG3, PRDM2, RB1CC1*) along with the natural killer receptor *KLRC1* were also down regulated in BAT.

10.1371/journal.pone.0057145.t003

###### Selection of the genes significantly different between BAT samples and control white matter samples, with a 2*-*fold difference in expression levels.

![](pone.0057145.t003){#pone-0057145-t003-3}

  Genebank                                                                           Description                                    Symbol      FC     Corrected *p-value*
  -------------------------------------------------- ---------------------------------------------------------------------------- ----------- ------- ---------------------
  **Genes up-regulated in BAT compared to CTRL**                                                                                                      
  ***Cell growth and proliferation***                                                                                                                 
  AW157070                                                                 epidermal growth factor receptor                          EGFR       8.0          0.0389
  AW007532                                                              Homo sapiens cDNA clone IMAGE:2500861                       IGFBP5      2.8          0.0253
  NM_001321                                                              cysteine and glycine-rich protein 2                         CSRP2      2.4          0.0314
  NM_001392                                                                Homo sapiens dystrobrevin, alpha                          DTNA       2.4          0.0295
  NM_002167                                                                   inhibitor of DNA binding 3                              ID3       3.3          0.0468
  AI313324                                                                          histone H2A.1                                  HIST2H2AA    2.6          0.0468
  ***Cell adhesion/motility***                                                                                                                        
  NM_001078                                                               vascular cell adhesion molecule 1                          VCAM1      3.4          0.0159
  U82164                                                                             CD99 antigen                                    CD99       2.7          0.0218
  NM_005709                                                                       Usher syndrome 1C                                  USH1C      2.6          0.0192
  NM_021077                                                                          neuromedin B                                     NMB       2.3          0.0468
  BF674349                                                       transcriptional co-activator with PDZ-binding motif                  TAZ       2.7          0.0468
  AU157932                                                                             palladin                                      PALLD      2.3          0.0256
  ***Apoptosis***                                                                                                                                     
  NM_005460                                                              synuclein, alpha interacting protein                       SNCAIP      2.8           0.05
  ***Unknown function***                                                                                                                              
  AU154455                                                               Homo sapiens cDNA clone NT2RP4001145                        T1A-2      2.4          0.0314
  NM_022074                                                                        FLJ22794 protein                                FLJ22794     2.1          0.0192
  **Genes down-regulated in BAT compared to CTRL**                                                                                                    
  ***Angiogenesis***                                                                                                                                  
  NM_001704                                                            brain-specific angiogenesis inhibitor 3                       BAI3      −2.8          0.0468
  ***Transcription***                                                                                                                                 
  AF208967                                                                      paternally expressed 3                               PEG3      −5.6          0.0159
  AI810712                                                                     hepatic leukemia factor                                HLF      −5.5          0.0496
  NM_004538                                                              nucleosome assembly protein 1-like 3                       NAP1L3     −3.3          0.0496
  AL136629                                                                            TSPY-like                                     TSPYL1     −3.2          0.0468
  AV721430                                                                  transcription factor 7-like 2                           TCF7L2     −2.3          0.0496
  AI096375                                                                         KIAA1750 protein                                 TSPYL5     −2.3          0.0168
  NM_012231                                                            PR domain containing 2, with ZNF domain                       PRDM2     −2.5          0.0496
  AA488899                                                                   protein associated with Myc                            MYCBP2     −2.0          0.00518
  BG402105                                                                   RB1-inducible coiled-coil 1                            RB1CC1     −2.5          0.0192
  Z98884                                                             calmodulin binding transcription activator 1                   CAMTA1     −2.6          0.0468
  AB020663                                                                            Dmx-like 2                                     DMXL2     −2.0          0.0496
  AL050331                                                Human DNA sequence from clone RP3-486I3 on chromosome 6q22.1--22.3        TSPYL4     −2.2          0.0314
  ***Signal transduction***                                                                                                                           
  NM_002738                                                                    protein kinase C, beta 1                             PRKCB1     −11.3         0.0496
  NM_007023                                                            RAP guanine-nucleotide-exchange factor 4                     RAPGEF4    −7.0          0.0496
  NM_000807                                                       gamma-aminobutyric acid (GABA) A receptor, alpha 2                GABRA2     −4.4          0.0158
  NM_015678                                                                          neurobeachin                                    NBEA      −3.5          0.0496
  AB020717                                                                          synaptojanin 1                                   SYNJ1     −2.9          0.0468
  BC000498                                                                   aspartate aminotransferase 1                            GOT1      −2.7          0.0496
  AB007896                                                          putative L-type neutral amino acid transporter                 KIAA0436    −2.6          0.0159
  NM_012093                                                                       adenylate kinase 5                                  AK5      −2.5          0.0468
  L39833                                               potassium voltage-gated channel, shaker-related subfamily, beta member 1     KCNAB1     −2.4          0.0496
  NM_014710                                                     G protein-coupled receptor associated sorting protein                GASP      −2.2          0.0496
  NM_014247                                                            Rap guanine nucleotide exchange factor 2                     RAPGEF2    −2.1          0.0131
  AF052117                                                                        chloride channel 4                                 CLCN4     −2.1          0.0468
  AB002390                                                                     lysosomal apyrase-like 1                             LYSAL1     −2.0          0.0302
  ***Extracellular matrix remodelling***                                                                                                              
  NM_000202                                                                     iduronate 2-sulfatase                                 IDS      −3.0          0.0496
  AU144167                                                                   collagen, type III, alpha 1                            COL3A1     −2.7          0.0468
  ***Growth***                                                                                                                                        
  NM_020988                                           guanine nucleotide binding protein alpha activating activity polypeptide O     GNAO1     −2.1          0.0192
  NM_000345                                                                        synuclein, alpha                                  SNCA      −2.1          0.0496
  NM_005025                                                                  serine proteinase inhibitor                           SERPINI1    −2.0          0.0192
  ***Adhesion***                                                                                                                                      
  AW190070                                                     ATPase, Ca++ transporting, cardiac muscle, slow twitch 2             ATP2A2     −2.5          0.0496
  AU144598                                                               contactin associated protein-like 2                        CNTNAP2    −2.4          0.0453
  NM_005045                                                                             reelin                                       RELN      −2.2           0.035
  ***Cytoskeleton***                                                                                                                                  
  AB011133                                                         microtubule associated serine/threonine kinase 3                  MAST3     −2.2          0.0158
  ***Defense***                                                                                                                                       
  NM_002260                                                     killer cell lectin-like receptor subfamily C, member 1               KLRC1     −5.0          0.0125
  ***Ubiquitin cycle***                                                                                                                               
  AV726900                                                                      Ring finger protein 20                               RNF20     −2.5          0.00518
  AL031178                                                                         F-box protein 9                                   FBXO9     −2.2          0.0496
  NM_018422                                                            pleckstrin and Sec7 domain containing 3                       PSD3      −2.5          0.0314
  ***Unknown***                                                                                                                                       
  AL050136                                                               Homo sapiens mRNA; cDNA DKFZp586L141                                  −2.2          0.0352
  NM_014951                                                                    Zinc finger protein 365                              ZNF365     −2.4          0.0192
  AF063591                                                                          CD200 molecule                                   CD200     −2.2          0.0159

Validation of Gene Expression by RT-PCR {#s3e}
---------------------------------------

A subset of 7 genes was selected for further analysis by qPCR ([Figure 4a](#pone-0057145-g004){ref-type="fig"}). The 2−ΔΔCt method was used to calculate fold changes in the expression levels of the selected genes in the comparison BAT vs CTRL samples. The qPCR results showed that the expression levels of *ID3, TAZ, EGFR, IGFBP5, USH1C* were increased in BAT samples, while the expression of *SERPINI1* and *KLRC1* was decreased. These results supported the validity of microarray results. KLRC1 was selected to assess differences in protein levels between BAT and CTRL samples by the means of western blot analysis ([Figure 4b](#pone-0057145-g004){ref-type="fig"}). KLRC1 was detected in all CTRL specimens, while a very weak signal was detectable in the BAT samples.

![Validation of gene-expression.\
(a) qPCR validation of a subset of genes differentially expressed between BAT and CTRL. White bars represent the fold change in the expression level between BAT and CTRL as indicated by microarray analysis, while grey bars represent the mean fold change of gene expression calculated by qPCR method. The expression of each gene was normalized to that of 18S ribosomal RNA in the same sample and fold change represents the mean signal of 5 independent samples. Each grey bar is the mean ± SEM of duplicate determinations for each gene in biological replicates. *P*-values (t-test) for ID3, TAZ, EGFR, IGFBP5, USH1C, SERPINI1, KLRC1 were 0.043; 0.12; 0.09; 0.02; 0.005; 0.0004; 0.003; respectively. (b) KLRC1 western blot analysis in BAT and CTRL white matter samples. β-actin protein level was used as an endogenous control for loading.](pone.0057145.g004){#pone-0057145-g004}

Array CGH {#s3f}
---------

A large number of mosaic genomic lesions were detected by aCGH in tumor samples. Some of these alterations, such as del (1p36), del (2p21), +7, del (6q27q29)/−6, *EGFR* (7p11.2), *MDM2* (12q15) and *CDK4* (12q14.3) amplification, −10, amplification of 15q24.1, del (17p13)/−17, −19, −22 were known to be associated with glioblastomas [@pone.0057145-Dahlback1], [@pone.0057145-Rao1].

Several tumor-associated lesions were also present in the BAT. Shared anomalies with ET were del(1p36), del(2p21), *MDM2* and *CDK4* amplification, amplification of 15q24.1, −19 and −22. The genetic changes of +7, del(6q27q29), *EGFR* amplification, −10, del (17p13) were limited to the ET. The summary of these results is shown in [Table 4](#pone-0057145-t004){ref-type="table"}.

10.1371/journal.pone.0057145.t004

###### Consistent anomalies observed in ET and BAT by a-CGH.

![](pone.0057145.t004){#pone-0057145-t004-4}

  Consistent anomalies                                   ET1                                          BAT1                            ET2                BAT2                 ET3                             BAT3
  -------------------------- ----------------------------------------------------------- ------------------------------- ------------------------------ ------ --------------------------------- -------------------------------
  del (1p36)                                +\[27645717--29259696\] (40%)                 +\[27645717--29259696\] (45%)   +\[5997076--55676921\] (50%)    −      +\[1009416--46806902\] (40%)     +\[1009416--46806902\] (45%)
  del (2p21)                                              −                                             −                              −                  −      +\[47450573--47510722\] (64%)    +\[46985724--47510722\] (70%)
  **+7**                                                  −                                             −                              \+                 −                   \+                                −
  **del (6q27q29)/−6**                        +Complete monosomy (34%)                                  −                              −                  −     +\[163542007--166844004\] (52%)                 −
  **amp EGFR (7p11.2)**                                   −                                             −                   +\[54571903--55349837\]       −                    −                                −
  −**10**                                                 −                                             −                           \+ (60%)              −                \+ (80%)                             −
  amp CDK4 (12q14.3)                           +\[64510897--64589846\]                       +\[64510897--64589846\]                   −                  −                    −                                −
  amp MDM2 (12q15)                             +\[67369376--68348402\]                       +\[67369376--68348402\]                   −                  −                    −                                −
  amp 15q24.1                 \+[\*](#nt101){ref-type="table-fn"}\[70483070--71401705\]      +\[70764425--71255997\]                   −                  −                    −                                −
  **del (17p13)(p53)/−17**                  +\[505704-- 40281123\] (17%)                                −                   +Complete monosomy (20%)      −        +Complete monosomy (40%)                     −
  −19                                                 \+ (30%)                                          −                           \+ (19%)              −                    −                            \+ (15%)
  −22                                                 \+ (38%)                                          −                           \+ (23%)              −                \+ (23%)                         \+ (20%)

further amplification in ET, with respect to BAT.

In bold: anomalies limited to ETs.

In square bracket: genomic positions (according to NCBI 36 build) of the observed anomalies.

In round brackets: mosaicism degree of the observed anomaly. The percentage of abnormal cells was inferred using the formula proposed by Valli et al. That formula cannot be applied to the amplified segments (EGFR, CDK4, MDM2 and 15q24.1) since their ploidy status is unknown.

Immunohistology {#s3g}
---------------

TAZ expression was found in the majority of GBM cells, predominantly in the cell nuclei ([Figure 5C](#pone-0057145-g005){ref-type="fig"}). Double-labelled ET samples revealed GFAP and TAZ co-expression when analyzed by confocal microscopy ([Figure 6A--C](#pone-0057145-g006){ref-type="fig"}). The majority of neoplastic cells expressed TAZ in the nucleus, and only few cells showed a cytoplasmatic staining ([Figure 6B, C](#pone-0057145-g006){ref-type="fig"}). As expected, GFAP was highly expressed in the cytoplasm of tumor cells ([Figure 5A](#pone-0057145-g005){ref-type="fig"}; [Figure 6A, C](#pone-0057145-g006){ref-type="fig"}). In ET samples, as expected, the majority of tumor cells exhibited strong specific EGFR immunopositivity ([Figure 7A](#pone-0057145-g007){ref-type="fig"}). The reactivity was strong on the cell membrane and less intense in the cytoplasm of the tumor cells. The same expression pattern was found for CD99 in the GBM cells ([Figure 7D](#pone-0057145-g007){ref-type="fig"}).

![Immunohistochemical staining for GFAP and TAZ in ET and BAT.\
The majority of GBM cells showed intense diffuse cytoplasmic staining for GFAP (A). In the BAT, only apparently normal and reactive astrocytes (black arrow) expressed GFAP protein (B). TAZ immunoreactivity, mainly nuclear, was uniformly expressed in the cells of the ET (C). In the BAT, TAZ positive cells were observed very infrequently (D*).* Original magnification, ×630 (A--D). Hematoxylin counterstain.](pone.0057145.g005){#pone-0057145-g005}

![Confocal microscopy images of GFAP (red) and TAZ (green) expression in ET and BAT.\
In the ET samples, GFAP was highly expressed in the cytoplasm of neoplastic cells (A; C). In the BAT, it was present in the body and cytoplasmic extensions of astrocytes (D; F). In the ET, TAZ was expressed predominantly in the nucleus (white arrowheads) and few cells also showed a cytoplasmic localization (yellow arrowhead) (B; C). Rarely, the GBM cells were negative for TAZ (arrow) (B; C). In the BAT, TAZ was almost undetectable. In the photograph shown, no expression of TAZ was observed (E; F). Scale bar: 20 µm.](pone.0057145.g006){#pone-0057145-g006}

![Immunohistochemical staining for EGFR and CD99 in ET, BAT and CTRL.\
In the ET samples, tumor cells showed intense staining for EGFR, mainly n the cell membrane (A). In the BAT, black arrow points to EGFR immunopositive reactive astrocytes (B). In the ET, CD99-immunoreactivity can be observed at the membrane level and in the cytoplasm (D). In the BAT, CD99 immunopositivity was found in reactive astrocytes (black arrow), in some normal glial cells (black arrowhead) (E). In the CTRL, immunoreactivity for EGFR or CD99 was rarely observed (C; F). Original magnification: x630 (A-B, D-E), x200 (C; F). Hematoxylin counterstain.](pone.0057145.g007){#pone-0057145-g007}

In BAT, GFAP immunostaining was displayed in both apparently normal and reactive astrocytes ([Figure 1C](#pone-0057145-g001){ref-type="fig"}; [Figure 5B](#pone-0057145-g005){ref-type="fig"}). The frequency of Ki67/MIB1 positive cells was always lower than 1% ([Figure 1D](#pone-0057145-g001){ref-type="fig"}). TAZ immunopositive nuclei were extremely rare ([Figure 5D](#pone-0057145-g005){ref-type="fig"}). Confocal microscopy of BAT samples confirmed that expression of TAZ was rarely seen in peritumoral tissue samples ([Figure 6E, F](#pone-0057145-g006){ref-type="fig"}), while apparently normal and reactive astrocytes were positive for GFAP staining ([Figure 6D, F](#pone-0057145-g006){ref-type="fig"}). In BAT, the EGFR immunopositivity was observed in reactive astrocytes ([Figure 7B](#pone-0057145-g007){ref-type="fig"}) as well as for CD99 that was also expressed in some normal cells ([Figure 7E](#pone-0057145-g007){ref-type="fig"}). The mean percentage of EGFR- and CD99-positive cells was higher in BAT (10.1±2.6 for EGFR and 11.5±2.8 for CD99) with respect to CTRL (3.2±0.1 and 2.7±0.2 for EGFR and CD199, respectively; [Figure 7C, F](#pone-0057145-g007){ref-type="fig"}).

In ET samples, CD133 cytoplasmic immunopositivity, visualized by immunofluorescence microscopy,was found in a moderate number of tumor cells ([Figure 8](#pone-0057145-g008){ref-type="fig"} A). In BAT, the same pattern of reactivity was observed in a low percentage (1.9±0.3) of reactive astrocytes and apparently normal cells ([Figure 8](#pone-0057145-g008){ref-type="fig"} B). A very low value (0.06±0.1) of CD133-positive cells was displayed in CTRL samples ([Figure 8C](#pone-0057145-g008){ref-type="fig"}).

![Immunofluorescence of CD133 expression in ET, BAT and CTRL.\
CD133 cytoplasmic immunopositivity (red) was observed in a moderate number of cells in the ET (A). In the BAT, the signal was present in reactive astrocytes (white arrows) and apparently normal cells (green arrow) (B). In CTRL samples, CD133-positive cells are extremely rare. In the field showed no CD133-positive cells are detected (C). Cell nuclei were marked with DAPI (blue). Original magnification: x400 (A, B, C).](pone.0057145.g008){#pone-0057145-g008}

Discussion {#s4}
==========

Few information is available about the peritumoral tissue sampled at least one cm from the macroscopic tumor border. By comparing the expression pattern of CTRL and BAT, we separated 57 genes which were differentially expressed in BAT against CTRL. These genes were also highly expressed in GBM suggesting that GBM and morphologically normal appearing BAT share a similar expression profile. In our study, the *EGFR* expression levels showed the largest difference between CTRL and BAT, being highly expressed in the latter. The *EGFR* gene is the most frequently amplified proto-oncogene in primary glioblastomas [@pone.0057145-HoiSang1]. Another growth factor receptor, *NMB*, was also overexpressed in BAT. We also found in BAT an up-regulation of *IGFBP5,* histone *HIST2H2AA* and transcription regulator *ID3.* All these elements are involved in proliferation and tumor progression [@pone.0057145-Wang1], [@pone.0057145-Tzeng1], [@pone.0057145-Vandeputte1].

In BAT, we also detected an over-expression of genes involved in cell motility, such as palladin, alpha-dystrobrevin (*DTNA*), *CD99* and *VCAM-1* [@pone.0057145-Wang1], [@pone.0057145-Boon1], [@pone.0057145-Lee1], [@pone.0057145-Manara1], [@pone.0057145-Scotlandi1], [@pone.0057145-Shih1]. We also found the over-expression of the transcription regulator *TAZ* in BAT. This molecule controls the expression of genes regulating cell migration and proliferation [@pone.0057145-Chan1], [@pone.0057145-Zhou1]. *TAZ* association with mesenchymal (MES) gene expression signature of glioblastoma, resulting in poor overall survival and treatment resistance has recently been emphasized [@pone.0057145-Bhat1].

The set of genes showing reduced expression in BAT included several ones previously described for their anti-oncogenic role, controlling intracellular signalling cascade and transcription molecular functions. Among these, the expression of *BAI3, PEG3, SNCA* has already been reported to be absent or significantly decreased in GBM and glioma cells [@pone.0057145-Kee1], [@pone.0057145-Kohda1], [@pone.0057145-Stefanova1].

Several genes down-regulated in BAT such as *PRDM2, TCF7L2, RB1CC1, ATP2A2* are involved in the pathogenesis of other type of cancers, but not in gliomas [@pone.0057145-Burwinkel1], [@pone.0057145-Endo1], [@pone.0057145-Folsom1], [@pone.0057145-Kontani1], [@pone.0057145-Korosec1], [@pone.0057145-Lal1]. Interestingly, *SYNJ1, NBEA, SERPINI1, CNTNAP2 and RELN,* which are known to be involved in neurogenesis, were down-regulated in BAT [@pone.0057145-Chen1], [@pone.0057145-Fatemi1], [@pone.0057145-Friedman1], [@pone.0057145-Mani1], [@pone.0057145-McAvoy1].

KLRC1, an inhibitory receptor for the non-classical MHC class I molecule HLA-E, has been involved in the inhibition of innate anti-glioma immune responses [@pone.0057145-Mittelbronn1]. In our study, we reported the strong down-regulation of KLRC1 in BAT samples, both at transcriptional and protein level. This finding suggests that an inhibition of a proper immune response may exist. A big limitation of this study is that the "normal" white matter control samples did not come from the same patients bearing the glioblastoma, but from different patients operated for non-neoplastic lesions. The ideal would have been that the white matter controls came from the same patient but very far from the tumor (possibly in the other hemisphere). Obviously, this is not possible in vivo, due to ethical problems, and is not feasible post mortem, because at that point, the spread of the disease possibly involves multiple areas of the brain [@pone.0057145-Burger1].

The differences between CTRL and BAT and the similarity of gene expression of BAT and GBM could be explained by the presence of infiltrative tumor cells that we were not able to detect at histological analysis. On this way, we performed the aCGH, a technique which is able to detect chromosome alterations only if these are present in a high percentage of cells. By comparing individual ET and BAT, we observed that BAT of two patients (BAT1 and BAT3) showed that almost all cells displayed anomalies consistently associated with GBM, but none of the cells of BAT2 displayed chromosomic anomalies known to be associated with GBM, even in the presence of several dysregulated genes. However, from a clinical point of view, the outcome of the patient whose BAT did not display any evident genomic change was similar to that of the other two patients. Obviously, in view of the small number of patients in the study, no conclusions on the relationship between genomic alterations of the BAT and survival can be drawn.

Overall, data interpretation is not easy. We can exclude that the differences in genes expression between CTRL and BAT reflect reactive changes as we have found the same level of gliosis, as determined by the presence of GFAP positive reactive astrocytes and the poor macrophages infiltration (data not shown). Undoubtedly, peritumor tissue sampled at 1 cm or more from the macroscopic tumor border presents frank gene/chromosome alterations. Some of these alterations were also present at the protein level, as shown by immunohistological analysis.

As a matter of fact, the mean percentage of EGFR- and CD99-positive cells in BAT was higher than 10%, while CD133 cytoplasmic immunopositivity was observed in a very low percentage (less than 2%) of reactive astrocytes and apparently normal cells. As CD133 is a marker of brain cancer stem cells, our data revealed that the amount of possible CD133 positive cancer stem cells was low in the BAT. Nonetheless, considerable experimental evidence for the existence of both CD133 positive and CD133 negative populations as tumor-initiating cells exists [@pone.0057145-Donovan1]. Therefore, we may have missed some putative cancer cells.

Undoubtedly, the array-based gene expression profile could result from a minority of cells, but this condition is in contrast with the array CGH results, showing chromosomal aberrations in the vast majority of cells.

On the other hand, the correlation between gene overexpression and encoded protein levels can also be weak.

All our experiments suggest that several tumor-like alterations are detectable in the BAT. Nevertheless, question remains about the nature of the cells populating the peritumour tissue. Two main hypotheses may support these findings and these hypotheses are not mutually exclusive. Our data could be explained by a dilution of genes expressed from tumor cells infiltrating the BAT samples: in fact the genes overexpressed in BAT against CTRL were also over-expressed in GBM but with a higher fold change. In fact, histological analysis may have missed the presence of some infiltrative tumor cells in the BAT. These cells could also be histologically undetectable, "dormant" infiltrating cells. [@pone.0057145-Mangiola3].

A possible role of cancer stem cells in determining genetic changes in the BAT is difficult to sustain, since we observed few CD133 positive cells in this area, but we may have missed CD133 negative cancer stem cells.

Alternatively, these findings could be supported by a relevant amount of cells that present a gene profile compatible with a precancerous state. The aCGH data seem to be in favour of this hypothesis. Of course, the truth may lie somewhere in between, and the recurrent tumor may arise from both infiltrating tumor cells (including histologically undetectable tumor cells, "dormant" tumor cells and possibly cancer stem cells) and from an interaction and recruitment of apparently normal cells in the peritumor tissue by infiltrating tumor cells. If the latter two hypotheses are true, our observations could reflect a change of the BAT, which may progress to tumor by acquiring genomic alterations characteristic of GBM. Some changes might be induced by the cross-talk between tumor cells and normal cells. A possible mechanism of this phenomenon can be explained through the transporting of microvesicles containing RNA and a number of mRNA transcripts, which may lead to induction of oncogenic processes in peritumoral normal cells [@pone.0057145-Skog1]. BAT may also bear traces of the tumor microenvironment in the form of microvescicles or exosomes transporting tumor mRNA or even genomic DNA, which could also partially explain our findings.

Whatever the correct explanation of our findings, further studies on the BAT are needed, in order to identify possible targets for future treatments.
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